Tempest Therapeutics

Tempest Therapeutics granted one employee nonqualified stock options to purchase 9,450 shares of its common stock, vesting over four years.

FDA allows phase 3 trial of amezalpat (TPST-1120) combined with Tecentriq and Avastin vs. standard care in unresectable/metastatic hepatocellular carcinoma. Aim is to assess overall and progression-free survival, with enrollment of 740 patients expected by March 2028.

TPST stock hits 52-week low at $0.92, down -71.84% in a year. Tempest Therapeutics advances cancer treatment with Roche, secures FDA agreement for Phase 3 study, and appoints Troy M. Wagner. InvestingPro highlights TPST's cash burn and weak margins but notes more cash than debt.

Tempest Therapeutics and Roche collaborate to advance amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab into a Phase 3 trial for first-line treatment of unresectable or metastatic hepatocellular carcinoma, with Tempest leading the study and Roche supplying atezolizumab globally. The companies aim to start the Phase 3 study in Q1 2025.

H.C. Wainwright reaffirms Buy rating and $47.00 target for Tempest Therapeutics (NASDAQ:TPST) after Roche drug supply agreement for Phase 3 1L HCC study. Tempest to sponsor study while Roche supplies atezolizumab. Successful EOP2 meeting with FDA on Phase 3 plan, including OS primary endpoint. Tempest needs $100 million for study, with $39.2 million cash as of Q2 2024. Roche agreement expected to save $30-50 million. Tempest aims to start pivotal study Q1 2025. Despite positive developments, Tempest faces financial challenges with -$31.66 million adjusted operating income in last 12 months.

Curis Inc. stock rose 6.53% to $5.38, with revenue of $2.55M and a net loss of $11.80M, EPS -$2.03. The biotech sector gained 0.32%, with Curis among active stocks. The company focuses on immuno-oncology and precision oncology drugs.

Tempest Therapeutics extends its stockholder rights plan to the Annual Meeting of Stockholders, aiming to protect stockholders from undervaluation and potential hostile takeovers.

Tempest Therapeutics, Inc. (NASDAQ:TPST) partners with Roche for Phase 3 trial of amezalpat, an oral cancer therapy, in 2025. The trial aims to improve first-line treatment for unresectable or metastatic hepatocellular carcinoma (HCC). Tempest retains development and commercial rights to amezalpat, which showed positive survival data in previous studies. The FDA approved the Phase 3 study design in August 2024, with potential early efficacy analysis shortening the study timeline.

Tempest Therapeutics granted two employees nonqualified stock options to purchase 79,500 shares of common stock, vesting over four years under the 2023 Inducement Plan.